Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Clinical trial NCT05714371 · COMPLETED
Trial details
- NCT number
- NCT05714371
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-10-02
- Primary completion
- 2022-01-27
- Enrollment
- 618
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.